First Biosimilar Of Infliximab Drug In India Was Launched By Ranbaxy Laboratories Ltd

First Biosimilar Of Infliximab Drug In India Was Launched By Ranbaxy Laboratories Ltd
Infimab, the first Remicade (Infliximab) biosimilar revealed to be successful in treating inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, psoriasis and psoriatic arthritis, was recently launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh by Ranbaxy Laboratories Ltd. Infimab, also known as BOW015, is entering the Indian market thanks to a partnership

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *